NCT00851409View on ClinicalTrials.gov

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2010

Conditions
Genetic DisordersHereditary Angioedema
Interventions
DRUG

Recombinant Human C1 Inhibitor

"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."

Trial Locations (2)

541103

Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department, Târgu Mureş

Unknown

For information on sites, please contact Pharming Technologies, Leiden

Sponsors
All Listed Sponsors
lead

Pharming Technologies B.V.

INDUSTRY